This site is intended only for healthcare professionals resident in the Republic of Ireland
MBS, most bothersome symptom.
*Study 303 is 1 of 3 Phase III trials with VYDURA or a 75 mg rimegepant tablet formulation bioequivalent to VYDURA in acute migraine treatment. For information on Studies 301 and 302, see the SmPC.1,3
†Participants who had not had an attack of moderate or severe pain intensity within 45 days of randomisation were instructed to return unused study medication and the eDiary to the study centre and complete all end-of-study procedures.2
MMDs, monthly migraine days.
‡This study evaluated a rimegepant 75 mg tablet formulation bioequivalent to VYDURA.3,4
§78 (21%) VYDURA-treated‡ patients and 95 (26%) placebo-treated patients had a history of chronic migraine, as assessed by the site PI according to the International Classification of Headache Disorders-3 criteria.4
||Permitted rescue medications during the 12-week double-blind treatment phase included triptans, non-steroidal anti-inflammatory drugs, paracetamol up to 1000 mg/day for a maximum of 2 consecutive days (including a fixed combination containing paracetamol 250 mg, aspirin 250 mg, and caffeine 65 mg), baclofen, antiemetics, and muscle relaxants. VYDURA‡ was not permitted as a rescue medication.4
¶This is the number of patients who were randomised and took at least one dose of VYDURA.5
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
Legal Category: S1B
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023